clinical genomics

1
WGM - May 2011 © 2002-2008 Health Level Seven ®, Inc. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven, Inc. Reg. U.S. Pat & TM Off Clinical Genomi Ongoing pilots: – Family History (“Pedigree”) is implemented in operational systems in the US and Europe • The CPP (Canonical Pedigree Project) is gaining momentum – Genetic Variation • v3 Genetic Variation is used in the European Commission Hypergenes project on essential hypertension • v2 (implementation guide over Lab v2.5.1) is piloted between Partners Healthcare & Intermountain Health Care Under ballot reconciliation: – CDA Implementation Guide for Genetic Testing Reports (developed with OHT MDHT) Ongoing standards development: – Genetic Variation • v2 extension of the published HL7 2.5.1 Clinical Genomic Lab Result Implementation Guide to support tumor profiling results. Pilot sites include Dana-Farber Cancer Institute (DFCI). • v3 Genetic Variation passed normative ballot as a CMET representing testing results – Cytogenetics in v2 and v3 specifications – Domain Analysis Model and respective DIM – Gene Expression v3 CMET – Genomic Specimen : adjustment to the universal Specimen CMET

Upload: ruby-tyler

Post on 30-Dec-2015

28 views

Category:

Documents


0 download

DESCRIPTION

Clinical Genomics. Ongoing pilots: Family History (“Pedigree”) is implemented in operational systems in the US and Europe The CPP (Canonical Pedigree Project) is gaining momentum Genetic Variation - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Clinical Genomics

WGM - May 2011

© 2002-2008 Health Level Seven ®, Inc. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven, Inc. Reg. U.S. Pat & TM Off

Clinical Genomics•Ongoing pilots:

– Family History (“Pedigree”) is implemented in operational systems in the US and Europe• The CPP (Canonical Pedigree Project) is gaining momentum

– Genetic Variation • v3 Genetic Variation is used in the European Commission Hypergenes project on essential hypertension• v2 (implementation guide over Lab v2.5.1) is piloted between Partners Healthcare & Intermountain Health Care

• Under ballot reconciliation:– CDA Implementation Guide for Genetic Testing Reports (developed with OHT MDHT)

• Ongoing standards development:– Genetic Variation

• v2 extension of the published HL7 2.5.1 Clinical Genomic Lab Result Implementation Guide to support tumor profiling results. Pilot sites include Dana-Farber Cancer Institute (DFCI).• v3 Genetic Variation passed normative ballot as a CMET representing testing results

– Cytogenetics in v2 and v3 specifications – Domain Analysis Model and respective DIM– Gene Expression v3 CMET– Genomic Specimen : adjustment to the universal Specimen CMET